Blood Protein Biomarkers Predict Outcome of a Patient’s COVID-19 Infection
|
By LabMedica International staff writers Posted on 08 Jun 2020 |
|
![Image: Transmission electron microscope image showing SARS-CoV-2, the virus that causes COVID-19 (Photo courtesy of [U.S.] National Institute of Allergy and Infectious Diseases)](https://globetechcdn.com/mobile_labmedica/images/stories/articles/article_images/2020-06-08/GMS-073B.jpg "Image: Transmission electron microscope image showing SARS-CoV-2, the virus that causes COVID-19 (Photo courtesy of [U.S.] National Institute of Allergy and Infectious Diseases)")
Image: Transmission electron microscope image showing SARS-CoV-2, the virus that causes COVID-19 (Photo courtesy of [U.S.] National Institute of Allergy and Infectious Diseases)
A panel of blood biomarkers in patients with COVID-19 has demonstrated the potential to predict the severity of their symptoms and likely outcome of the infection.
By the beginning of June 2020 more than six million people worldwide had become ill with COVID-19, caused by the SARS-CoV-2 coronavirus, and more than 380,000 had perished. Thus, a method to predict the likely trajectory of the disease in the individual patient is an urgent requirement.
Toward this end, investigators at the Francis Crick Institute (London, UK) and Charité – Universitätsmedizin Berlin (Germany) developed a platform for ultra-high throughput serum and plasma proteomics (protein analysis). This method was designed to adhere to ISO13485 standardization for MS-high-flow liquid chromatography to facilitate implementation in clinical laboratories.
The platform was developed at the Francis Crick Institute and applied to analyze serum of 31 COVID-19 patients at the Berlin University Hospital Charité. Results were further validated in 17 patients with COVID-19 at the same hospital and in 15 healthy individuals.
Results of the analyses identified 27 potential biomarkers in the blood that were differentially expressed depending on the WHO severity grade of COVID-19. The biomarkers included complement factors, components of the coagulation system, inflammation modulators, and pro-inflammatory proteins upstream and downstream of interleukin. The low-cost workflow quantified 180 proteomes per day per mass spectrometer, enabled high precision quantification, and reduced batch effects for large-scale and longitudinal studies.
Senior author Dr. Markus Ralser, group leader at the Francis Crick Institute and professor of biochemistry at Charité – Universitätsmedizin Berlin, said, "The robust method we have used in this study is a valuable and powerful tool to predict disease progression and also find potential targets for treatments. Our approach could also be easily applied to other diseases, now and in the future, to understand more about their effects on the body."
The COVID-19 blood biomarker study was published in the May 2020 online edition of the journal Cell Systems.
Related Links:
Francis Crick Institute
Charité – Universitätsmedizin Berlin
By the beginning of June 2020 more than six million people worldwide had become ill with COVID-19, caused by the SARS-CoV-2 coronavirus, and more than 380,000 had perished. Thus, a method to predict the likely trajectory of the disease in the individual patient is an urgent requirement.
Toward this end, investigators at the Francis Crick Institute (London, UK) and Charité – Universitätsmedizin Berlin (Germany) developed a platform for ultra-high throughput serum and plasma proteomics (protein analysis). This method was designed to adhere to ISO13485 standardization for MS-high-flow liquid chromatography to facilitate implementation in clinical laboratories.
The platform was developed at the Francis Crick Institute and applied to analyze serum of 31 COVID-19 patients at the Berlin University Hospital Charité. Results were further validated in 17 patients with COVID-19 at the same hospital and in 15 healthy individuals.
Results of the analyses identified 27 potential biomarkers in the blood that were differentially expressed depending on the WHO severity grade of COVID-19. The biomarkers included complement factors, components of the coagulation system, inflammation modulators, and pro-inflammatory proteins upstream and downstream of interleukin. The low-cost workflow quantified 180 proteomes per day per mass spectrometer, enabled high precision quantification, and reduced batch effects for large-scale and longitudinal studies.
Senior author Dr. Markus Ralser, group leader at the Francis Crick Institute and professor of biochemistry at Charité – Universitätsmedizin Berlin, said, "The robust method we have used in this study is a valuable and powerful tool to predict disease progression and also find potential targets for treatments. Our approach could also be easily applied to other diseases, now and in the future, to understand more about their effects on the body."
The COVID-19 blood biomarker study was published in the May 2020 online edition of the journal Cell Systems.
Related Links:
Francis Crick Institute
Charité – Universitätsmedizin Berlin
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series
Latest Molecular Diagnostics News
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
Channels
Clinical Chemistry
view channel
3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more.jpg "Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)")
POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more
Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
The conventional methods for measuring free cortisol, the body's stress hormone, from blood or saliva are quite demanding and require sample processing. The most common method, therefore, involves collecting... Read more
Hematology
view channel
Next Generation Instrument Screens for Hemoglobin Disorders in Newborns
Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more
First 4-in-1 Nucleic Acid Test for Arbovirus Screening to Reduce Risk of Transfusion-Transmitted Infections
Arboviruses represent an emerging global health threat, exacerbated by climate change and increased international travel that is facilitating their spread across new regions. Chikungunya, dengue, West... Read more
POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy
Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy
Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read moreImmunology
view channel
Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more
AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more
Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Microbiology
view channel
Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more
Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
Antimicrobial resistance (AMR) is a serious global public health concern that claims millions of lives every year. It primarily results from the inappropriate and excessive use of antibiotics, which reduces... Read more
New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
According to the World Health Organization (WHO), an estimated 354 million individuals globally are afflicted with chronic hepatitis B or C. These viruses are the leading causes of liver cirrhosis, liver... Read more
1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read morePathology
view channel.jpg "Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)")
Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
Tuberculosis (TB), the leading cause of death from an infectious disease globally, is a contagious bacterial infection that primarily spreads through the coughing of patients with active pulmonary TB.... Read moreTechnology
view channel
New Diagnostic System Achieves PCR Testing Accuracy
While PCR tests are the gold standard of accuracy for virology testing, they come with limitations such as complexity, the need for skilled lab operators, and longer result times. They also require complex... Read more
DNA Biosensor Enables Early Diagnosis of Cervical Cancer
Molybdenum disulfide (MoS2), recognized for its potential to form two-dimensional nanosheets like graphene, is a material that's increasingly catching the eye of the scientific community.... Read more
Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
Microfluidics, which are miniature devices that control the flow of liquids and facilitate chemical reactions, play a key role in disease detection from small samples of blood or other fluids.... Read more
Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
Home testing gained significant importance during the COVID-19 pandemic, yet the availability of rapid tests is limited, and most of them can only drive one liquid across the strip, leading to continued... Read moreIndustry
view channel_1.jpg "Image: Thermo Fisher will distribute Bio-Techne products across Europe (Photo courtesy of 123RF)")
Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
Thermo Fisher Scientific (Waltham, MA USA) has entered into a strategic distribution agreement with Bio-Techne Corporation (Minneapolis, MN, USA), resulting in a significant collaboration between two industry... Read more
ECCMID Congress Name Changes to ESCMID Global
Over the last few years, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID, Basel, Switzerland) has evolved remarkably. The society is now stronger and broader than ever before... Read more
